Cyclo(Arg-Gly-Asp-D-Phe-Cys)

Product overview
Catalog Number
PPH08-0265
Sequence
cyclo (Arg-Gly-Asp-D-Phe-Cys)
Target
RGD Tumor Targeting Peptide (linker additions via Cys) (May Require Further Derivatization Before Use), The Arg-Gly-Asp (RGD) sequence is a highly conserved integrin recognition sequence within fibronectin.
Description
RGD peptides are fibronectin fragments that guide integrin-induced cell attachment, proliferation and migration. Cyclic RGD peptides containing D-Phe, such as cRGDfV, are selective antagonists of ανβ3 and ανβ5 integrins that inhibit the binding of these integrins to vitronectin. cRGDfV inhibits angiogenesis and vascular remodeling. cRGDfV also blocks cellular adhesion and may induce apoptosis in cells bearing surface ανβ3 integrin, although its anti-tumor effect may be primarily due to its antiangiogenic action. C(RGDfC), a RGD tumor-targeting peptide, which binds to αvβ3 receptors. C(RGDfC) can be easily conjugated to drugs as combretastatin or surfaces. For the control peptide c(RADfC) see H-7232. c(RGDfC) (M.W. 578.65) C24H34N8O7S RGD Tumor Targeting Peptide (linker additions via Cys) (May require further derivatization before use)
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

1mg, 5mg, 25mg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
  • For research use only
  • Not for use in diagnostic procedures

€44,00 – €724,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us